Article Sidebar
Views PDF: 340
VALUE OF SERUM FRUCTOSAMIN IN REFLECTING FASTING GLUCOSE IN DIABETES MELLITUS WITH CHRONIC KIDNEY DISEASE
Main Article Content
Abstract
Objective: 1) Determine serum fructosamin concentration in diabetic patients with chronic kidney disease. 2) Determine the relationship between serum fructosamin concentration with fasting blood glucose and HbA1C concentration in diabetic patients with chronic kidney disease. Methods: A case control study was conducted with 3 groups: a group of diabetic patients with glomerular filtration rate <60ml/p (diabetic group with chronic kidney disease), a group of diabetic patients with glomerular filtration rate ≥60ml/p (diabetes without chronic kidney disease) and a group of healthy people. All patients have serum fructosamin, fasting blood glucose, HbA1C and other relevant biochemical parameteres measured. Results: There were 136 patients included into 3 groups: 50 diabetic patients with chronic kidney disease, 56 diabetic patients without chronic kidney disease and a healthy group of 30 people. (1) The mean concentration of Frucosamine in the diabetic group with chronic kidney disease was 316.1 ± 53.2 µmo/l, higher than in the healthy group 60 ± 27.4 µmo/l (p<0.05); lower than diabetes in the group without disease 22.4 ± 39.4 µmo/l, but there was no statistical significance (p>0.05). (2) Fructosamin has a sufficient correlation with HbA1C in diabetic patients with chronic kidney disease (r=0.388); and has the same correlation with fasting blood glucose and HbA1C concentration in diabetic patients without chronic kidney disease (r=0.487, r=0.466). Conclusion: (1) Fructosamin concentration has a positive relationship with fasting blood glucose and HbA1C concentration in the group of diabetic patients. (2) Fructosamin concentration reflects fasting blood glucose, is not affected by chronic renal failure and anemia, so it can be used in monitoring and controlling blood glucose in diabetic patients with chronic kidney disease.
Article Details
Keywords
Diabetes mellitus, Chronic kidney disease, Fructosamin, HbA1C
References
2. Tạ Văn Bình, và cộng sự, (2017), "Sống khỏe với đái tháo đường", Tạp chí đái tháo đường, tr. 1- 26.
3. Cindy George, Tandi E. Matsha, Marizna Korf, Annalise E. Zemlin, et al, (2020), "The agreement between fasting glucose and markers of chronic glycaemic exposure in individuals with and without chronic kidney disease: a cross-sectional study", BMC Nephrol, 21 (1), pp. 32.
4. Neelofar K, Ahmad J, (2019), "A comparative analysis of fructosamine with other risk factors for kidney dysfunction in diabetic patients with or without chronic kidney disease", Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 13 (1), pp. 240-244.
5. Shohat N, Tarabichi M, Tan T L, Goswami K, et al, (2019), "2019 John Insall Award: Fructosamine is a better glycaemic marker compared with glycated haemoglobin (HbA1C) in predicting adverse outcomes following total knee arthroplasty: a prospective multicentre study", Bone Joint J, 101-b (7_Supple_C).
6. Chen H S, Wu T E, Lin H D, Jap T S, et al, (2010), "Hemoglobin A(1c) and fructosamine for assessing glycemic control in diabetic patients with CKD stages 3 and 4", Am J Kidney Dis, 55 (5), pp. 867-874.
7. Lê Thị HươngThu (2016), "Nồng độ fructosamin huyết thanh trong đánh giá mức độ kiểm soát đường máu ở bệnh nhân đái tháo đường typ 2 điều trị ngoại trú tại bệnh viện trung ương thái nguyên", tr. 31-41 .
8. Nguyễn Thu Giang, Lê Thị Hương Lan, (2018), "Nồng độ fructosamin huyết tương và mối liên quan với một số chỉ số sinh hóa máu ở bệnh nhân đái tháo đường type 2 điều trị tại bệnh viện trung ương thái nguyên", tr. 35-55.